Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). Eligible patients were adults with newly diagnosed untreated, unresectab...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2020-01, Vol.99 (4), p.e18732-e18732 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e18732 |
|---|---|
| container_issue | 4 |
| container_start_page | e18732 |
| container_title | Medicine (Baltimore) |
| container_volume | 99 |
| creator | Qiu, Xiangnan Li, Jing Zhou, Han Zhang, Meng Jiang, Changchen Shen, Zetian Zhu, XiXu Li, Aomei Che, Yuxin Wu, Tiancong Wang, Zhen |
| description | The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC).
Eligible patients were adults with newly diagnosed untreated, unresectable esophageal cancer in stages I to IV with lymph node metastases or cervical esophageal cancer. Patients received nedaplatin 25 mg/m per day on day 1-3, raltitrexed 3 mg/m on days 1 repeated every 21 days for 2 cycles, and combined concurrent radiotherapy (2 Gy/fraction, total dose of 60 Gy).
Thirty patients were included with squamous cell carcinoma. The median follow-up duration was 24 months. The overall response rate was 90%. The 1-year and 2-year overall survival rates for all patients were 70.4% and 55.7% with a median survival time of 30 months, and the median progression free survival was 20 month. The major toxicities were leukopenia and thrombopenia, with grade 3 to 4 leukopenia and thrombopenia were 50% and 30% of patients.
Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC. |
| doi_str_mv | 10.1097/MD.0000000000018732 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7004679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31977864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4503-212bc4c195eb590bfee4a20109ff35f11ee1faf6c64a21a71bf64b65dfaf15313</originalsourceid><addsrcrecordid>eNpdkN1u1DAUhC0EokvhCZCQXyCtf-PmBgltaYvUqjdwbZ04xxvTJA520qVvj-lC-fGNpfHMZ80Q8pazE84ac3pzfsL-HH5mpHhGNlzLutJNrZ6TDWNCV6Yx6oi8yvlrMUkj1EtyJHljzFmtNuRuGye3poTTQl2PY0zQhbj0mGB-oPuw9DTBsIQl4XfsKEwdnbCDeYAlTDThLow4UR8TxRznHnYIA83fVhjjmqnDYaAOkgtTHOE1eeFhyPjm131Mvlx8_Ly9qq5vLz9tP1xXTmkmK8FF65TjjcZWN6z1iAoEK529l9pzjsg9-NrVReZgeOtr1da6K2Jpz-UxeX_gzms7YudKt9LBzimMkB5shGD_fZlCb3fx3hrGVG2aApAHgEsx54T-KcuZ_bm9vTm3_29fUu_-_vYp83vsYlAHwz4OC6Z8N6x7TLYvky39I0-bRlSCiYIUilVFEVL-AEM_k30</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma</title><source>IngentaConnect Backfiles</source><source>MEDLINE</source><source>PubMed Central(OpenAccess)</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Wolters Kluwer Open Access</source><creator>Qiu, Xiangnan ; Li, Jing ; Zhou, Han ; Zhang, Meng ; Jiang, Changchen ; Shen, Zetian ; Zhu, XiXu ; Li, Aomei ; Che, Yuxin ; Wu, Tiancong ; Wang, Zhen</creator><creatorcontrib>Qiu, Xiangnan ; Li, Jing ; Zhou, Han ; Zhang, Meng ; Jiang, Changchen ; Shen, Zetian ; Zhu, XiXu ; Li, Aomei ; Che, Yuxin ; Wu, Tiancong ; Wang, Zhen</creatorcontrib><description>The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC).
Eligible patients were adults with newly diagnosed untreated, unresectable esophageal cancer in stages I to IV with lymph node metastases or cervical esophageal cancer. Patients received nedaplatin 25 mg/m per day on day 1-3, raltitrexed 3 mg/m on days 1 repeated every 21 days for 2 cycles, and combined concurrent radiotherapy (2 Gy/fraction, total dose of 60 Gy).
Thirty patients were included with squamous cell carcinoma. The median follow-up duration was 24 months. The overall response rate was 90%. The 1-year and 2-year overall survival rates for all patients were 70.4% and 55.7% with a median survival time of 30 months, and the median progression free survival was 20 month. The major toxicities were leukopenia and thrombopenia, with grade 3 to 4 leukopenia and thrombopenia were 50% and 30% of patients.
Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000018732</identifier><identifier>PMID: 31977864</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Aged ; Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Chemoradiotherapy - methods ; Clinical Trial/Experimental Study ; Dose-Response Relationship, Radiation ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Esophageal Squamous Cell Carcinoma - pathology ; Esophageal Squamous Cell Carcinoma - therapy ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Quinazolines - administration & dosage ; Quinazolines - adverse effects ; Retrospective Studies ; Thiophenes - administration & dosage ; Thiophenes - adverse effects ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2020-01, Vol.99 (4), p.e18732-e18732</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4503-212bc4c195eb590bfee4a20109ff35f11ee1faf6c64a21a71bf64b65dfaf15313</citedby><cites>FETCH-LOGICAL-c4503-212bc4c195eb590bfee4a20109ff35f11ee1faf6c64a21a71bf64b65dfaf15313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004679/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004679/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31977864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiu, Xiangnan</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Zhou, Han</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Jiang, Changchen</creatorcontrib><creatorcontrib>Shen, Zetian</creatorcontrib><creatorcontrib>Zhu, XiXu</creatorcontrib><creatorcontrib>Li, Aomei</creatorcontrib><creatorcontrib>Che, Yuxin</creatorcontrib><creatorcontrib>Wu, Tiancong</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><title>Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC).
Eligible patients were adults with newly diagnosed untreated, unresectable esophageal cancer in stages I to IV with lymph node metastases or cervical esophageal cancer. Patients received nedaplatin 25 mg/m per day on day 1-3, raltitrexed 3 mg/m on days 1 repeated every 21 days for 2 cycles, and combined concurrent radiotherapy (2 Gy/fraction, total dose of 60 Gy).
Thirty patients were included with squamous cell carcinoma. The median follow-up duration was 24 months. The overall response rate was 90%. The 1-year and 2-year overall survival rates for all patients were 70.4% and 55.7% with a median survival time of 30 months, and the median progression free survival was 20 month. The major toxicities were leukopenia and thrombopenia, with grade 3 to 4 leukopenia and thrombopenia were 50% and 30% of patients.
Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC.</description><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Chemoradiotherapy - methods</subject><subject>Clinical Trial/Experimental Study</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophageal Squamous Cell Carcinoma - pathology</subject><subject>Esophageal Squamous Cell Carcinoma - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Quinazolines - administration & dosage</subject><subject>Quinazolines - adverse effects</subject><subject>Retrospective Studies</subject><subject>Thiophenes - administration & dosage</subject><subject>Thiophenes - adverse effects</subject><subject>Treatment Outcome</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkN1u1DAUhC0EokvhCZCQXyCtf-PmBgltaYvUqjdwbZ04xxvTJA520qVvj-lC-fGNpfHMZ80Q8pazE84ac3pzfsL-HH5mpHhGNlzLutJNrZ6TDWNCV6Yx6oi8yvlrMUkj1EtyJHljzFmtNuRuGye3poTTQl2PY0zQhbj0mGB-oPuw9DTBsIQl4XfsKEwdnbCDeYAlTDThLow4UR8TxRznHnYIA83fVhjjmqnDYaAOkgtTHOE1eeFhyPjm131Mvlx8_Ly9qq5vLz9tP1xXTmkmK8FF65TjjcZWN6z1iAoEK529l9pzjsg9-NrVReZgeOtr1da6K2Jpz-UxeX_gzms7YudKt9LBzimMkB5shGD_fZlCb3fx3hrGVG2aApAHgEsx54T-KcuZ_bm9vTm3_29fUu_-_vYp83vsYlAHwz4OC6Z8N6x7TLYvky39I0-bRlSCiYIUilVFEVL-AEM_k30</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Qiu, Xiangnan</creator><creator>Li, Jing</creator><creator>Zhou, Han</creator><creator>Zhang, Meng</creator><creator>Jiang, Changchen</creator><creator>Shen, Zetian</creator><creator>Zhu, XiXu</creator><creator>Li, Aomei</creator><creator>Che, Yuxin</creator><creator>Wu, Tiancong</creator><creator>Wang, Zhen</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma</title><author>Qiu, Xiangnan ; Li, Jing ; Zhou, Han ; Zhang, Meng ; Jiang, Changchen ; Shen, Zetian ; Zhu, XiXu ; Li, Aomei ; Che, Yuxin ; Wu, Tiancong ; Wang, Zhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4503-212bc4c195eb590bfee4a20109ff35f11ee1faf6c64a21a71bf64b65dfaf15313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Chemoradiotherapy - methods</topic><topic>Clinical Trial/Experimental Study</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophageal Squamous Cell Carcinoma - pathology</topic><topic>Esophageal Squamous Cell Carcinoma - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Quinazolines - administration & dosage</topic><topic>Quinazolines - adverse effects</topic><topic>Retrospective Studies</topic><topic>Thiophenes - administration & dosage</topic><topic>Thiophenes - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiu, Xiangnan</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><creatorcontrib>Zhou, Han</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Jiang, Changchen</creatorcontrib><creatorcontrib>Shen, Zetian</creatorcontrib><creatorcontrib>Zhu, XiXu</creatorcontrib><creatorcontrib>Li, Aomei</creatorcontrib><creatorcontrib>Che, Yuxin</creatorcontrib><creatorcontrib>Wu, Tiancong</creatorcontrib><creatorcontrib>Wang, Zhen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiu, Xiangnan</au><au>Li, Jing</au><au>Zhou, Han</au><au>Zhang, Meng</au><au>Jiang, Changchen</au><au>Shen, Zetian</au><au>Zhu, XiXu</au><au>Li, Aomei</au><au>Che, Yuxin</au><au>Wu, Tiancong</au><au>Wang, Zhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>99</volume><issue>4</issue><spage>e18732</spage><epage>e18732</epage><pages>e18732-e18732</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The aim of the study reported here was to evaluate the feasibility and safety of raltitrexed and nedaplatin with concurrent radiotherapy in patients with unresectable, locally advanced esophageal squamous cell carcinoma (ESCC).
Eligible patients were adults with newly diagnosed untreated, unresectable esophageal cancer in stages I to IV with lymph node metastases or cervical esophageal cancer. Patients received nedaplatin 25 mg/m per day on day 1-3, raltitrexed 3 mg/m on days 1 repeated every 21 days for 2 cycles, and combined concurrent radiotherapy (2 Gy/fraction, total dose of 60 Gy).
Thirty patients were included with squamous cell carcinoma. The median follow-up duration was 24 months. The overall response rate was 90%. The 1-year and 2-year overall survival rates for all patients were 70.4% and 55.7% with a median survival time of 30 months, and the median progression free survival was 20 month. The major toxicities were leukopenia and thrombopenia, with grade 3 to 4 leukopenia and thrombopenia were 50% and 30% of patients.
Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>31977864</pmid><doi>10.1097/MD.0000000000018732</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2020-01, Vol.99 (4), p.e18732-e18732 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7004679 |
| source | IngentaConnect Backfiles; MEDLINE; PubMed Central(OpenAccess); DOAJ Directory of Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library; Wolters Kluwer Open Access |
| subjects | Aged Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Chemoradiotherapy - methods Clinical Trial/Experimental Study Dose-Response Relationship, Radiation Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Esophageal Squamous Cell Carcinoma - pathology Esophageal Squamous Cell Carcinoma - therapy Female Humans Longitudinal Studies Male Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Quinazolines - administration & dosage Quinazolines - adverse effects Retrospective Studies Thiophenes - administration & dosage Thiophenes - adverse effects Treatment Outcome |
| title | Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A27%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concurrent%20chemoradiotherapy%20with%20raltitrexed%20and%20nedaplatin%20regimen%20for%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=Medicine%20(Baltimore)&rft.au=Qiu,%20Xiangnan&rft.date=2020-01-01&rft.volume=99&rft.issue=4&rft.spage=e18732&rft.epage=e18732&rft.pages=e18732-e18732&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000018732&rft_dat=%3Cpubmed_cross%3E31977864%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31977864&rfr_iscdi=true |